TA1 vs Vitamin D3 Injection
A side-by-side research comparison of TA1 and Vitamin D3 Injection across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | TA1 | Vitamin D3 Injection |
|---|---|---|
| Full name | Thymosin Alpha-1 (TA1 - Clinical Form) | Cholecalciferol (Vitamin D3) Injectable |
| Category | Immune Support | Immune Support |
| Status | Approved internationally (not FDA-approved) | Compounded supplement |
| Mechanism | Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades. | Converts to 25-hydroxyvitamin D then to active 1,25-dihydroxyvitamin D. Modulates over 200 genes including those for immune function, calcium absorption, bone remodeling, and hormone production. |
| Molecular weight | 3108.3 Da | 384.64 Da |
| Half-life | ~2-3 hours | ~15 days (storage form) |
| Bioavailability | ~85% subcutaneous | ~100% IM |
| Typical dose | 1.6 mg | 50,000-100,000 IU |
| Frequency | 2x per week | Weekly to monthly |
| Route | Subcutaneous injection | Intramuscular injection |
TA1 reported benefits
- Standardized immune enhancement
- Proven antiviral adjunct
- Cancer immunotherapy support
- Vaccine response enhancement
Vitamin D3 Injection reported benefits
- Rapid deficiency correction
- Immune system optimization
- Bone health
- Hormone support
- Mood improvement
- Reduced inflammation
Related comparisons
Research and educational reference only. Not medical advice.